LEAP2 reduces ad libitum food intake and attenuates postprandial glucose excursions in men with obesity
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
The naturally occurring peptide, liver-expressed antimicrobial peptide 2 (LEAP2), has gained interest as a ghrelin receptor antagonist. We previously reported reduced food intake and plasma glucose-lowering effects of LEAP2 infusion in lean healthy men; however, the effects of this competitive antagonist and inverse agonist of the ghrelin receptor in men with obesity have not been investigated. In the present study, 20 men with obesity were enrolled in a randomized, double-blind, placebo-controlled, crossover study comprising two experimental visits each involving a ~5-hour intravenous infusion of LEAP2 (infusion rate 40 pmol/kg/min) or placebo during which a liquid mixed meal test and a subsequent ad libitum meal test were performed. The LEAP2 infusion resulted in a 5-fold increase in plasma concentrations of LEAP2 compared to placebo. The infusion lowered postprandial plasma glucose levels and reduced ad libitum food intake by ~12%. We conclude that a continuous intravenous LEAP2 infusion reduces glycemia and food intake in men with obesity, supporting further exploration of LEAP2’s therapeutic potential in obesity and related metabolic conditions.
Fields of Study & Subjects
Regulation of Appetite and Obesity
Adipokines
Inflammation
and Metabolic Diseases
Diabetes Treatment and Management
Publication details
- Publication date
- 30 March 2026
- Language
- EN